Performance of matrices developed to identify patients with early rheumatoid arthritis with rapid radiographic progression despite methotrexate therapy: an external validation study based on the ESPOIR cohort data.
Fiche publication
Date publication
janvier 2016
Journal
RMD open
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GUILLEMIN Francis
Tous les auteurs :
Granger B, Combe B, Le Loet X, Saraux A, Guillemin F, Fautrel B
Lien Pubmed
Résumé
Use of prediction matrices of risk or rapid radiographic progression (RRP) for early rheumatoid arthritis (RA) in clinical practice could help to better rationalise the first line of treatment. Before use, they must be validated in populations that have not participated in their construction. The main objective is to use the ESPOIR cohort to validate the performance of 3 matrices (ASPIRE, BEST and SONORA) to predict patients at high risk of RRP at 1 year of disease despite initial treatment with methotrexate (MTX).
Mots clés
Early Rheumatoid Arthritis, Epidemiology, Rheumatoid Arthritis, Treatment
Référence
RMD Open. 2016 ;2(1):e000245